medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2026, Número 3

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2026; 37 (3)


¿Se debe cambiar o no la batería del desfibrilador cardioversor implantable, debido a que se está agotando y a que nunca se ha descargado?

Álvarez de la Cadena-Sillas J, Asensio-Lafuente E, Aguilar-Linares J, Jiménez-Cruz M

Idioma: Inglés [English version]
Referencias bibliográficas: 67
Paginas: 136-145
Archivo PDF: 839.09 Kb.


RESUMEN

El uso de desfibriladores cardioversores implantables (DCI) ha demostrado ser eficaz y útil para mejorar las tasas de supervivencia tras una muerte súbita cardíaca (MSC) en pacientes con indicaciones clínicas para su uso. Sin embargo, el reemplazo de un generador que nunca ha administrado terapias eléctricas y que ahora presenta agotamiento de la batería puede generar controversia. En este artículo, analizamos diferentes factores que deben tenerse en cuenta antes del reemplazo del generador en este subgrupo de pacientes. Los puntos principales son la mejora o no de la fracción de eyección del ventrículo izquierdo (FEVI), la reestratificación del riesgo al momento del reemplazo, la presencia o ausencia de terapias inapropiadas del DCI, la gravedad de la enfermedad cardíaca, el pronóstico al momento de la sustitución, las comorbilidades actuales, la esperanza de vida y la edad avanzada, las posibles complicaciones del nuevo procedimiento, la posibilidad de reducir la intensidad del dispositivo, los factores económicos, así como la decisión del propio paciente y la discusión clínica subyacente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Shen F, Lu K, Cheng Z, Feng X. Effect of implantablecardioverter defibrillator on primary prevention onsudden cardiac death in high-risk patients. Am J TranslRes. 2023; 15 (2): 1352-1359.

  2. Zeppenfeld K, Tfelt J, de Riva M, Gregers B, BehrE, Blom N et al. Guidelines for the managementof patients with ventricular arrhythmias and theprevention of sudden cardiac death. Developed bythe task force for the management of patients withventricular arrhythmias and the prevention of suddencardiac death of the European Society of Cardiology(ESC) Endorsed by the Association for EuropeanPaediatric and Congenital Cardiology (AEPC). EurHeart J. 2022; 43 (40): 3997-4126.

  3. Al-Khatib S, Stevenson W, Ackerman M, BryantW, Callans D, Curtiss A et al. 2017 AHA/ACC/HRSguideline for management of patients with ventriculararrhythmias and the prevention of sudden cardiacdeath: a report of the American College of Cardiology/American Heart Association Task Force on ClinicalPractice Guidelines and the Heart Rhythm Society.Circulation. 2017; 128 (13): e272-e391.

  4. Freeman J, Torre M, Sanders P, Varma N, Baykaner T,deering T et al. Variability in implantable cardioverterdefibrillator battery longevity. Heart Rhythm. 2026; 23(5): 1162-1171. doi: 10.1016/j.hrthm.2025.05.031.

  5. Green A, Jenkins A, Masoudi F, Magid D, Kutner J, LeffB et al. Decision-making experiences of patients withimplantable cardioverter defibrillators. Pacing ClinElectrophysiol. 2016; 39 (10): 1061-1069.

  6. McCarthy K, Locke A, Coletti M, Young D, MerchantF, Kramer D. Outcomes following implantablecardioverter defibrillator generator replacement inadults: a systematic review. Heart Rhythm. 2020; 17(6): 1036-1042.

  7. Myerburg RJ, Junttila MJ. Sudden cardiac death causedby coronary heart disease. Circulation. 2012; 125 (8):1043-1052.

  8. Stecker EC, Reinier K, Marijon E, Narayanan K,Teodorescu C, Uy-Evanado A et al. Public healthburden of sudden cardiac death in the United States.Circ Arrhythm Electrophysiol. 2014; 7 (2): 212-217.

  9. Agesen FN, Lynge TH, Blanche P, Banner J, Prescott E,Jabbari R et al. Temporal trends and sex differences insudden cardiac death in the Copenhagen City HeartStudy. Heart. 2021; 107 (16): 1303-1309.

  10. Khalid N, Abdullah M, Higgins C, Ahmad B, MunshiH, Hasnat M et al. Cardiac arrest mortality acrosstime and space: A national analysis with forecast to2035. J Clin Med. 2025; 14 (14): 4851, doi: 10.3390/jcm14144851.

  11. Bhide P, Bhanderi H, Vyas C, Ghose M, kakalia M,Weiner S et al. Mortality trends of cardiac arrestfrom 1999-2020 and the impact of the COVID-19pandemic on cardiac arrest mortality. Crit Care. 2023;164 (4): A1678-A1679.

  12. Fernández I, Osca J, Alzueta J. Spanish implantablecardioverter defibrillator registry. 19th official reportof the heart rhythm association of the Spanish Societyof Cardiology. Rev Esp Cardiol. 2023; 76 (11): 922-935.

  13. Sanders G, Hiatky M, Owens D. Cost-effectiveness ofimplantable cardioverter-defibrillators. N Eng J Med.2005; 353 (14): 1471-11480.

  14. Ribera A, Giménez E, Oristrell G, Osorio D, MarsalJR, García L et al. Cost-effectiveness of implantablecardioverter-defibrillators for primary prevention ofsudden cardiac death. Rev Esp Cardiol. 2022; 75 (1):12-21.

  15. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D,Sheldon RS et al. Canadian implantable defibrillatorstudy (CIDS): a randomized trial of the implantablecardioverer defibrillator against amiodarone.Circulation. 2000; 101 (11): 1297-1302.

  16. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomizedcomparison of antiarrhythmic drug therapy withimplantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg(CASH). Circulation. 2000; 102 (7): 748-754.

  17. Borne RT, Katz D, Betz J, Peterson PN, Masoudi FA.Implantable cardioverter-defibrillators for secondaryprevention of sudden cardiac death: A review. JAm Heart Assoc. 2017; 6 (3): e005515. Availableon: https://www.ahajournals.org/doi/pdf/10.1161/JAHA.117.005515

  18. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, KuckKH, Zipes DP et al. Meta-analysis of the implantablecardioverter defibrillator secondary preventiontrials.AVID, CASH and CIDS studies. Antiarrhythmics vsImplantable Defibrillator study. Cardiac Arrest StudyHamburg. Canadian Implantable Defibrillator Study.Eur Heart J. 2000; 21 (24): 2071-2078.

  19. Zabel M, Willems R, Lubinski A, Bauer A, BrugadaJ, Conen D et al. Clinical effectiveness of primaryprevention implantable cardioverter-defibrillators:results of the EU-CERT-ICD controlled multicentrecohort study. Eur Heart J. 2020; 41 (36): 3437-3447.

  20. Sticherling C, Arendacka B, Svendsen JH, Wijers S,Friede T, Stockinger J et al. Sex differences in outcomesof primary prevention implantable cardioverterdefibrillatortherapy: combined registry data from elevenEuropean countries. Europace. 2018; 20 (6): 963-970.

  21. Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, BuitenMS, de Bie MK et al. Prophylactic use of implantablecardioverter-defibrillators in the prevention of suddencardiac death in dialysis patients. Circulation. 2019;139 (23): 2628-2638.

  22. Junttila MJ, Pelli A, Kentta TV, Friede T, Willems R,Bergau L et al. Appropriate shocks and mortality inpatients with versus without diabetes with prophylacticimplantable cardioverter defibrillators. Diabetes Care.2020; 43 (1): 196-200.

  23. Antiarrhythmic Versus Implantable Defibrillators (AVID)investigators. A comparison of antiarrhythmic-drugtherapy with implantable defibrillators in patientsresuscitated from near-fatal ventricular arrhythmias.N Engl J Med. 1997; 337 (22): 1576-1583.

  24. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L,Korup E et al. Defibrillator implantation in patientswith nonischemic systolic heart failure. N Engl J Med.2016; 375 (13): 1221-1230.

  25. Al-Khatib S, Friedman D, Sanders G. When is it safe noto re-implant an implantable cardioverter defibrillatorat the time of battery depletion? Card ElectrophysiolClin. 2018; 10 (1): 137-144.

  26. López C, Di Toro D. Implantable cardioverterdefibrillator: 35 years after a historical milestone in LatinAmerica Medicina (B Aires). 2021; 81 (5): 882-883.

  27. Franca AT, Martins LNA, de Oliveira DM, de CastilhoFM, Branco BC, Wilnes B et al. Evaluation of patientswith implantable cardioverter-defibrillator in a LatinAmerican tertiary center. J Cardiovasc Electrophysiol.2024; 35 (4): 675-684. doi: 10.1111/jce.16201.

  28. Higuera L, Holbrook R, Wherry K, Rodriguez DA,Cuesta A, Valencia J et al. Comparison of costeffectivenessof implantable cardioverter defibrillatortherapy in patients for primary prevention inLatin America: an analysis using the Improve SCAstudy. J Med Econ. 2021; 24 (1): 173-180. doi:10.1080/13696998.2021.1877451.

  29. Buxton E, Lee L, Fisher D, Josephson M, PrystowskyE, Hafley G. A randomized study of the preventionof sudden death in patients with coronary arterydisease. Multicenter Unsustained Tachycardia TrialInvestigators. N Engl J Med. 1999; 341 (25): 1882-1890.

  30. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ,Cannom DS et al. Prophylactic implantation of adefibrillator in patients with myocardial infarction andreduced ejection fraction. N Engl J Med. 2002; 346(12): 877-883.

  31. Schrage B, Uijl A, Benson L, Westermann D, StahlbergM, Stolfo D et al. Association between use of primarypreventionimplantable cardioverter-defibrillator andmortality in patients with heart failure: a prospectivepropensity score-matched analysis from the SwedishHeart Failure Registry. Circulation. 2019; 140 (19):1530-1539.

  32. Carlson S, Gravely A, Adabag S. Trajectory of leftventricular ejection fraction among individuals eligiblefor implantable cardioverter-defibrillator. Pacing ClinElectrophysiol. 2021; 44 (5): 800-806.

  33. Bilchick K, Wang Y, Curtis J, Shadman R, Dardas T,Anand I et al. Survival probability and survival benefitassociated with primary prevention cardioverterdefibrillatorgenerator changes. J Am Heart Assoc. 2022;11 (13): e023743. doi: 10.1161/JAHA.121.023743.

  34. Cárdenas E, Asensio E, Orea A, Castillo L, Narváez R,Dorantes J et al. Impact of optimal medical therapyon the arrhythmias and heart rate variability detectedwith 24-hour Holter in a series of patients from a heartfailure clinic. Rev Invest Clin. 2004; 56 (5): 609-614.

  35. Pozzi A, Abete R, Tavano E, Kristensen S, Rea F, LorioA et al. Sacubitril/valsartan and arrhythmic burdenin patients with heart failure and reduced ejectionfraction: a systematic review and meta-analysis. HeartFail Rev. 2023; 28 (6): 1395-1403.

  36. De Masi G, Palama Z, Longo S, Barba F, Robles A, NestiM et al. Effect of dapaglifozin on ventricular arrhythmicevents in heart failure patients with an implantablecardioverter defibrillator. Cardiol Res. 2025; 16 (2):140-152.

  37. Ruwald M, Ruwald A, Brock J, Gislason G, LindhardtT, Cosedis J et al. Temporal incidence of appropriateand inappropriate therapy and mortality in secondaryprevention ICD patients by cardiac diagnosis. JACCClin Electrophysiol. 2021; 7 (6): 781-792.

  38. Quinto L, Sánchez-Somonte P, Alarcón F, Garre P,Castillo A, San Antonio R et al. Ventricular tachycardiaburden reduction after substrate ablation: predictorsof recurrence. Heart Rhythm. 2021; 18 (6): 896-904.

  39. Rordorf R, Cornara S, Klersy C, Savastano S,Vicentini A, Sanzo A et al. Incidence of appropriateanti-tachycardia therapies after elective generatorreplacement in patient with heart failure initiallyimplanted with a defibrillator for primary prevention:results of a meta-analysis. Int J Cardiol. 2019; 283:122-127.

  40. Madhavan M, Waks J, Friedman P, Kramer D, BuxtonA, Noseworthy P et al. Outcomes after implantablecardioverter-defibrillator generator replacement forprimary prevention of sudden cardiac death. CircArrhythm Electrophysiol. 2016; 9 (3): e003283.

  41. Weng W, Sapp J, Doucette S, MacIntyre C, Gray C,Gardner M et al. Benefit of implantable cardioverterdefibrillatorgenerator replacement in a primaryprevention population-based cohort. JACC ClinElectrophysiol. 2017; 3 (10): 1180-1189.

  42. Gras D, Clémenty N, Ploux S, Guyomar Y, Legallois D,Segreti L et al. CRT-D replacement strategy: results ofthe BioCONTINUE study. J Interv Card Electrophysiol.2023; 66 (5): 1201-1209.

  43. Sebag F, Lellouche N, Chen Z, Tritar A, O’Neill M, Gill J etal. Positive response to cardiac resynchronization therapyreduces arrhythmic events after elective generatorchange in patients with primary prevention CRT-D. JCardiovasc Electrophysiol. 2014; 25 (12): 1368-1375.

  44. Nakou E, Simantirakis E, Kallergis E, Nakos K, VardasP. Cardiac resynchronization therapy (CRT) devicereplacement considerations: Upgrade or downgrade?A complex decision in the current clinical setting. EPEuropace. 2017; 19 (5): 705-711.

  45. Shadman R, Poole J, Dardas T, Mozaffarian D, ClelandJ, Swedberg K et al. A novel method to predict theproportional risk of sudden cardiac death in heartfailure: derivation of the Seattle Proportional RiskModel. Heart Rhythm. 2015; 12: 2069-2077.

  46. Levy W, Hellkamp A, Mark D, Poole J, ShadmanR, Dardas TF et al. Improving the use of primaryprevention ICD therapy with validated patient-centricrisk estimates. JACC Clin Electrophysiol. 2018; 4 (8):1089-1102.

  47. Levy W, Li Y, Reed S, Zile M, Shadman R, Dardas Tet al. Does the implantable cardioverter-defibrillatorbenefit vary with the estimated proportional risk ofsudden death in heart failure patients? JACC ClinElectrophysiol. 2017; 3 (3): 291-298.

  48. Bilchick K, Wang Y, Cheng A, Curtis J, DharmarajanK, Stukenborg G et al. Seattle heart failure andproportional risk models predict benefit fromimplantable cardioverter-defibrillators. J Am CollCardiol. 2017; 69 (21): 2606-2618.

  49. Meier C, Eisenblatter M, Gielen S. Myocardial LateGadolinium Enhancement (LGE) in Cardiac MagneticResonance Imaging (CMR)—An important risk markerfor cardiac disease. J Cardiovasc Dev Dis. 2024; 11(2): 40.

  50. Prasad S, Akbari T, Bishop M, Halliday B, Leyva F,Marchlinski F. Late gadolinium enhancement andsudden cardiac death. Eur Heart J. 2025; 46 (36):3555-3568. doi: 10.1093/eurheartj/ehaf464.

  51. Akerstrom F, Pachon M, Puchol A, Jimenez J, SegoviaD, Rodriguez L et al. Chronic right ventricular apicalpacing: adverse effects and current therapeuticstrategies to minimize them. Int J Cardiol. 2014; 173(3): 351-360.

  52. Gierula J, Cubbon R, Jamil H, Byrom R, Baxter PD,Pavitt S et al. Cardiac resynchronization therapy inpacemaker-dependent patients with left ventriculardysfunction. Europace. 2013; 15 (11): 1609-1614.

  53. Thomas I, Wang Y, See V, Minges C, Curtis J, HsuJ. Outcomes following implantable cardioverterdefibrillatorgenerator replacement in patients withrecovered left ventricular systolic function: the nationalcardiovascular data registry. Heart Rhythm. 2019; 16(5): 733-740.

  54. Zhuo J, Chen C, Lin J, Wang J, Fu F. A long-term clinicalcomparative study of left bundle branch pacing versusbiventricular pacing in patients with heart failure andcomplete left bundle branch block. Heart Vessels.2025; 40 (8): 707-717.

  55. Kini V, Soufi M, Deo R, Epstein A, Bala R, Riley M etal. Appropriateness of primary prevention implantablecardioverter-defibrillators at the time of generatorreplacement: are indications still met? J Am CollCardiol. 2014; 63 (22): 2388-2394.

  56. Ruwald M, Solomon D, Foster E, Kutyifa V, RuwaldC, Sherazi S et al. Left ventricular ejection fractionnormalization in cardiac resynchronization therapy andrisk of ventricular arrhythmias and clinical outcomes:results from the Multicenter Automatic DefibrillatorImplantation Trial with Cardiac ResynchronizationTherapy (MADIT-CRT) trial. Circulation. 2014; 130(25): 2278-2286.

  57. Ahmed A, Auricchio A, Mittal S, Pickett R, WilkoffB, Jacobsen L et al. Mortality benefit among primaryprevention implantable cardioverter-defibrillatorrecipients on contemporary heart failure treatment.JACC Clinical EP. 2024; 10 (5): 916-926.

  58. Erkapic D, Sperzel J, Stiller S, Meltendorf U, Mermi J,Wegscheider K et al. Long-term benefit of implantablecardioverter/defibrillator therapy after elective devicereplacement: results of the INcidence free SUrvivalafter ICD REplacement (INSURE) trial--a prospectivemulticentre study. Eur Heart J. 2013; 34 (2): 130-137.doi: 10.1093/eurheartj/ehs177.

  59. Singh SN, Wininger M, Raitt M, Adabag S, Moore H,Rottman JN et al. Efficacy and safety of implantablecardioverter-defibrillator implantation in the elderly-The I-70 study: a randomized clinical trial. HeartRhythm O2. 2024; 5 (6): 365-373. doi: 10.1016/j.hroo.2024.04.010.

  60. Poole J, Gleva M, Mela T, Chung M, Uslan D, Birge Ret al. Complication rates associated with pacemakeror implantable cardioverter-defibrillator generatorreplacements and up-grade procedures. Results fromthe REPLACE study. Circulation. 2010; 16: 1553-1561

  61. Phillipon F, O’Hara G, Champagne J, Hohnloser S,Glickson M, Neuzner J, et al. Rate, time course andpredictors of implantable cardioverter-defibrillatorinfections: an analysis from the SIMPLE trial. Can JCardiol. 2020; 2 (5): 354-359.

  62. Wazni O, Epstein LM, Carrillo RG, Love C, Adler SW,Riggio DW et al. Lead mining in the contemporarysetting: the LExICon study: a retrospective observationalstudy of consecutive laser lead extractions. J Am CollCardiol. 2010; 55 (6): 579-586.

  63. Wilkoff BL, Love CJ, Byrd CL, Bongiorni MG, CarrilloRG, Crossley GH 3rd et al. Transvenous shunt removal:Heart Rhythm Society Expert consensus on facilities,training, indications, and patient management: thisdocument was endorsed by the American HeartAssociation (AHA). Heart Rate. 2009; 6 (7): 1085-1104.

  64. Martínez M, Pombo M, Recio A, Ayesta A, DatinoT. Considerations involved in elective generatorreplacement of implantable cardioverter-defibrillators:balancing risks, benefits and individual factors. Rev EspCardiol. 2024; 77 (1): 2-5.

  65. Wright G, Klein G, Gula L. Ethical and legal perspectiveof implantable cardioverter defibrillator deactivationor implantable cardioverter defibrillator generatorreplacement in the elderly. Curr Opin Cardiol. 2013;28 (1): 43-49.

  66. Merchant F, Quest T, Leon A, El-Chami M. Implantablecardioverter defibrillators at end of battery life:opportunities for risk (re)-stratification in ICDrecipients. J Am Coll Cardiol. 2016; 67 (4): 435-444.

  67. Demarchi A, Cornara S, Sanzo A, Savastano S, PetracciB, Vicentini B et al. Incidence of ventricular arrhythmiasand one-year predictors of mortality in patients treatedwith implantable cardioverter-defibrillator undergoinggenerator replacement. J Am Heart Assoc. 2021; 10(4): e018090.




2020     |     www.medigraphic.com